Omnicell Reports Q4 Revenue Growth of 2% to $314M, Unveils Titan XT
Omnicell's Q4 revenues increased 2% to $314 million and full-year 2025 sales rose 7% to $1.185 billion, while ARR reached $635.6 million. The company posted a GAAP net loss of $2 million in Q4 versus $16 million income a year ago and launched Titan XT dispensing system.
1. Q4 and Full Year Financial Results
In Q4 2025, Omnicell delivered total revenues of $314 million, reflecting a 2% increase versus Q4 2024. For the full fiscal year, Omnicell reported revenues of $1.185 billion, up 7% year-over-year. The company recorded a GAAP net loss of $2 million (−$0.05 per share) in the quarter compared with GAAP net income of $16 million ($0.34 per share) in Q4 2024. On a non-GAAP basis, Omnicell reported net income of $18 million ($0.40 per share) for Q4, down from $28 million ($0.60 per share) a year ago. Annual non-GAAP net income for 2025 was $75 million ($1.62 per share), versus $79 million ($1.71 per share) in 2024.
2. Revenue Drivers and Recurring Revenue Growth
Strength in technical service offerings, SaaS and Expert Services, and consumables underpinned the 2% quarterly revenue growth. In 2025, consumables and services accounted for the majority of the company’s Annual Recurring Revenue (ARR), which rose to $635.6 million at year-end, up 9.6% from $580.0 million a year earlier. Product bookings for the year totaled $535 million, reflecting a 4% decline as the company cycles through its Titan XT upgrade rollout. Total product backlog remained robust at $640.3 million, with $435.2 million expected to convert to revenue within 12 months.
3. Cash Flow, Balance Sheet and Liquidity
Operating cash flow in Q4 2025 was $30 million, down from $56 million in the same period last year, driven by timing of receivables and project deployments. At December 31, 2025, Omnicell held $197 million in cash and cash equivalents and $168 million of net debt. The company maintained full access to its $350 million revolving credit facility with zero drawn, providing ample liquidity to support product development, strategic investments and potential acquisitions.
4. Strategic Initiatives and 2026 Outlook
Omnicell launched Titan XT in December 2025—an enterprise-grade automated dispensing system designed to integrate advanced analytics with pharmacy and nursing workflows. Management highlighted that Titan XT bookings in Q4 have already contributed to the year-end backlog and expect it to drive upgrade cycles through 2026. CEO Randall Lipps reaffirmed guidance that full-year 2026 revenues, ARR growth and product bookings will each exceed the midpoint of prior ranges, targeting sustainable, profitable revenue growth supported by recurring services and consumables expansion.